GlassScriptPhysician profile
Samantha A Marrone
NPI 1780030130
$22,233.55
in general payments reported to CMS, 2019-2025
35 companies · $4,997 in 2025
The $4,997 reported for 2025 was more than what 88% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,083 · 2020: $865 · 2021: $1,960 · 2022: $3,113 · 2023: $4,389 · 2024: $4,826 · 2025: $4,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,564.73 |
| Education | $646.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,115.40 | 2019-2025 | |
| Janssen Biotech, INC. | $1,450.20 | 2021-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $1,412.88 | 2022-2025 | Sotyktu |
| Pfizer INC. | $1,325.76 | 2019-2025 | |
| Amgen INC. | $1,325.32 | 2020-2025 | Otezla, Otezla, Enbrel |
| Janssen Scientific Affairs, LLC | $1,282.78 | 2021-2025 | Tremfya |
| Galderma Laboratories, L.P. | $1,214.40 | 2019-2025 | Aklief, Oracea, Epsolay |
| Regeneron Healthcare Solutions, INC. | $892.32 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $846.55 | 2021-2025 | Ilumya |
| Lilly USA, LLC | $792.14 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $774.29 | 2023-2025 | Zoryve |
| Genzyme Corporation | $761.74 | 2021-2025 | |
| Incyte Corporation | $746.09 | 2022-2025 | Opzelura |
| Ucb, INC. | $566.75 | 2020-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $545.73 | 2021-2025 | Adbry |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $469.14 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $417.09 | 2021-2025 | Jublia, Cabtreo, Arazlo |
| Journey Medical Corporation | $379.07 | 2022-2025 | |
| Dermavant Sciences, INC. | $340.98 | 2022-2024 | Vtama |
| Almirall LLC | $294.88 | 2020-2025 | Klisyri, Seysara |
| Epi Health, LLC | $181.86 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $175.10 | 2024-2025 | |
| Botanix Sb INC | $149.45 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $142.37 | 2020-2025 | |
| Stemline Therapeutics INC. | $122.40 | 2020 | |
| Celgene Corporation | $82.66 | 2019 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Merck Sharp & Dohme LLC | $66.58 | 2019 | |
| Fresenius Kabi USA, LLC | $65.45 | 2023-2024 | Idacio |
| Verrica Pharmaceuticals INC. | $57.93 | 2023-2025 | Ycanth |
| Sebela Pharmaceuticals INC. | $53.57 | 2022-2023 | Naftin |
| Organon LLC | $37.74 | 2025 | Nexplanon |
| Helsinn Therapeutics (U.S.), INC. | $28.13 | 2022 | |
| Biofrontera INC. | $21.11 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Vyne Pharmaceuticals INC. | $15.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Marrone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.